Last updated: August 22, 2026
Clobetasol propionate is a super-high-potency topical corticosteroid sold mainly at 0.05% strength. The largest commercial opportunities are differentiated vehicles, improved tolerability, non-greasy delivery, scalp and nail targeting, and products that reduce application burden. The active ingredient is well established, so commercial protection depends more on formulation performance, delivery devices, manufacturing controls, and regulatory positioning than on new chemical-entity exclusivity.
What is the commercial position of clobetasol propionate?
Clobetasol propionate is approved for short-term treatment of corticosteroid-responsive dermatoses, including psoriasis and eczema. FDA labeling generally limits treatment to two consecutive weeks and 50 grams per week because of the risks associated with very-high-potency corticosteroids, including local skin atrophy and hypothalamic-pituitary-adrenal-axis suppression.[1-4]
The product is available in multiple dosage forms:
| Dosage form |
Representative product |
Commercial purpose |
| Cream |
Temovate and generics |
General inflammatory dermatoses; lower-grease vehicle |
| Ointment |
Temovate and generics |
Occlusive treatment for thick, dry plaques |
| Gel |
Cormax and generics |
Rapid-spreading, non-occlusive application |
| Solution |
Generic clobetasol solution |
Scalp and hair-bearing areas |
| Foam |
Olux and generic equivalents |
Scalp, body, and hair-bearing areas; cosmetic acceptability |
| Shampoo |
Clobex Shampoo |
Scalp psoriasis and wash-off delivery |
| Lotion |
Clobex Lotion and generic products |
Large-area or hairy-site application |
| Spray |
Clobex Spray and generic products |
Fast application across affected areas |
The market is largely genericized. Brand value remains strongest where the formulation solves a practical problem, such as scalp application, rapid evaporation, reduced residue, or easier dosing.
Which excipients are used in clobetasol propionate products?
Excipient selection determines drug release, skin penetration, sensory profile, stability, and patient adherence. Common excipient classes include:
| Excipient class |
Examples used or commercially relevant |
Primary function |
| Occlusive lipids |
White petrolatum, mineral oil, paraffin |
Increases hydration and contact time |
| Emollient esters |
Isopropyl myristate, glyceryl stearate |
Improves spreadability and skin feel |
| Alcohols |
Cetyl alcohol, stearyl alcohol, cetostearyl alcohol |
Thickening, emollience, cream structure |
| Humectants and solvents |
Propylene glycol, glycerin, ethanol |
Solubilization, hydration, evaporation |
| Surfactants |
Sodium lauryl sulfate, polysorbates, nonionic emulsifiers |
Emulsification and wetting |
| Gelling agents |
Carbomers, cellulose derivatives |
Viscosity and residence time |
| Preservatives |
Parabens, phenoxyethanol, benzyl alcohol |
Microbial protection |
| Propellants |
Hydrocarbon propellants |
Foam generation and delivery |
| Buffers |
Citric acid, citrate salts, phosphate systems |
pH control |
| Chelators |
Disodium EDTA |
Metal-ion control and preservative support |
Clobetasol propionate is lipophilic and poorly water soluble. The formulation therefore must balance solubilization with thermodynamic activity. A vehicle that holds the drug too tightly can reduce release from the formulation. A vehicle that increases partitioning into the stratum corneum can improve efficacy but also increase local adverse effects and systemic exposure.
How do cream and ointment excipients affect performance?
Ointments typically provide the highest occlusion. Petrolatum-based systems hydrate the stratum corneum, increase residence time, and can improve corticosteroid penetration. Their disadvantages are greasiness, transfer to clothing, poor cosmetic acceptability, and limited suitability for scalp or hairy areas.
Creams use an oil-in-water or water-in-oil emulsion to reduce residue. Their commercial advantage is broader patient acceptability. Surfactants, fatty alcohols, and emulsifiers must be selected to prevent phase separation while minimizing irritation. Sodium lauryl sulfate can improve wetting and emulsification but may be poorly tolerated by patients with sensitive or inflamed skin.
Propylene glycol is commercially useful as a solvent and humectant. It can improve drug solubilization and delivery, but concentration must be controlled because it can cause irritation or allergic contact dermatitis in susceptible users. This creates an opportunity for propylene-glycol-free products aimed at sensitive-skin populations.
What excipients are important in clobetasol foam?
Foam products use volatile solvents, emulsifiers, fatty alcohols, and hydrocarbon propellants. A representative clobetasol foam formulation contains ethanol, propylene glycol, cetyl alcohol, stearyl alcohol, polysorbate 60, citric acid, potassium citrate, and hydrocarbon propellants.[5]
Foam has several commercial advantages:
- It spreads through hair-bearing areas more easily than ointment.
- It leaves less residue than petrolatum-based systems.
- It can be applied quickly to scalp plaques.
- Evaporation can produce a dry after-feel.
The principal development risks are flammability, pressure control, valve performance, can compatibility, dose uniformity, and cold-temperature behavior. Hydrocarbon propellants also create storage, shipping, and manufacturing requirements. A non-aerosol foam or mechanically generated foam could reduce some supply-chain risks, but it may require a new device and more complex regulatory characterization.
What excipient strategies can differentiate clobetasol propionate?
Propylene-glycol-free and low-irritation formulations
A low-irritation vehicle can target patients who discontinue treatment because of burning, stinging, or allergic reactions. Candidate approaches include:
- Replacing propylene glycol with glycerin, polyethylene glycol systems, or selected glycol alternatives.
- Reducing anionic surfactants.
- Using nonionic emulsifiers.
- Removing fragrances and unnecessary colorants.
- Optimizing pH toward a skin-compatible range.
The commercial claim is usually improved tolerability, not greater corticosteroid potency. Supporting data should include irritation, sensitization, drug release, skin permeation, and clinical adherence.
Low-grease cream and lotion systems
A light emulsion can compete with ointments on patient convenience. The formulation objective is rapid spreading without excessive evaporation or crystallization of clobetasol propionate. Key development variables include oil-phase composition, droplet size, rheology, preservative system, and drug particle or molecular state.
A lotion is particularly suitable for larger affected areas and hairy regions. It also creates room for metered-dose packaging, which can improve dosing consistency.
Scalp-targeted delivery
Scalp products are among the clearest formulation opportunities. Solutions, foams, shampoos, and sprays can address the limitations of creams and ointments. Relevant excipient and device choices include:
- Volatile ethanol-water systems for rapid drying.
- Film-forming polymers for residence time.
- Mild surfactants for shampoo products.
- Low-residue polymers for hair-bearing areas.
- Metered pumps for spray dose control.
- Applicator tips that separate hair and direct product to the scalp.
A scalp product must balance residence time with washability. Excessive film formation can create flaking or cosmetic problems, while a highly volatile solution may shorten skin contact.
Wash-off and pulse-delivery systems
Clobetasol shampoo is designed for scalp psoriasis and provides a wash-off format. The technical challenge is achieving adequate drug deposition during a limited contact period. Surfactant selection, viscosity, wetting, foam behavior, and rinse-off kinetics directly affect performance.
Potential follow-on products include higher-deposition shampoos, short-contact foams, and formulations designed for intermittent use. These products must not imply unrestricted chronic use because the pharmacologic risks of clobetasol remain relevant regardless of vehicle.
Nail and palmoplantar delivery
Nail psoriasis and thick palmoplantar plaques create penetration barriers. Commercial development could focus on:
- Film-forming solutions.
- Anhydrous gels.
- Occlusive patch or film systems.
- Microemulsion vehicles.
- Combinations with keratolytic excipients such as urea or salicylic acid, where compatible with the regulatory pathway.
- Applicator systems that improve localization.
These products face higher technical and regulatory risk because penetration enhancement may increase local or systemic corticosteroid exposure. The active ingredient, excipient system, and delivery device must be assessed together.
What formulation patents and intellectual-property barriers apply?
The original composition-of-matter protection for clobetasol propionate is expired. Current commercial barriers are more likely to arise from formulation patents, device patents, process know-how, trademarks, and regulatory exclusivity associated with specific products.
Relevant IP categories include:
| IP category |
Potential claim scope |
Commercial relevance |
| Vehicle composition |
Solvent, oil, surfactant, polymer, pH, or phase structure |
Protects differentiated creams, gels, and lotions |
| Aerosol system |
Propellant, can, valve, foam structure, and pressure |
Protects foam products |
| Delivery device |
Metered pump, scalp applicator, spray geometry |
Limits direct substitution |
| Particle engineering |
Particle size, polymorph, suspension stability |
Supports release and uniformity claims |
| Combination therapy |
Clobetasol with keratolytics or other actives |
May support separate product positioning |
| Manufacturing process |
Mixing order, temperature, homogenization, filling |
Can protect scale-up and quality attributes |
| Method of use |
Treatment duration, body site, or dosing regimen |
May support labeling differentiation |
A generic applicant must address any unexpired patents listed in the FDA Orange Book for the reference product. Depending on the patent, an ANDA applicant may submit a Paragraph IV certification. A Paragraph IV certification can trigger patent litigation and, if litigation is filed within the statutory period, a 30-month stay of approval under the Hatch-Waxman framework.[6]
The Orange Book status must be assessed product by product. A patent listed for a foam, shampoo, spray, or lotion does not automatically apply to a cream or ointment. Formulation patents also may be vulnerable to design-around strategies involving different excipient concentrations, alternative propellants, or non-equivalent device configurations.
When does clobetasol propionate lose exclusivity?
Clobetasol propionate has already lost small-molecule composition-of-matter exclusivity. Generic competition exists across multiple dosage forms. The relevant commercial question is therefore not whether the molecule is protected, but whether a particular dosage form has remaining regulatory or patent barriers.
FDA regulatory exclusivity can still arise for a specific new formulation or indication. A 505(b)(2) product may rely partly on existing safety and efficacy information while submitting new formulation or clinical data. Potential advantages include:
- A new dosage form.
- A new route or delivery system.
- A new strength or dosing regimen.
- A new indication.
- A clinical benefit associated with tolerability or adherence.
The 505(b)(2) route can produce three-year exclusivity for certain approved changes supported by new clinical investigations, but that exclusivity does not block all generic versions of the older formulation. Five-year new-chemical-entity exclusivity is generally not available for a reformulation of an established active ingredient.[7]
What FDA and Orange Book issues affect clobetasol products?
FDA approval depends on the dosage form and the applicable application pathway. Conventional generic creams, ointments, gels, solutions, shampoos, lotions, and sprays generally proceed through ANDAs when a suitable reference product and bioequivalence pathway exist.
Topical products can present complex bioequivalence issues. Product sameness may involve:
- Active-ingredient concentration.
- Q1 sameness, meaning the same inactive ingredients.
- Q2 sameness, meaning the same concentrations.
- Q3 similarity in physical and structural characteristics.
- In vitro release testing.
- In vitro permeation testing.
- Comparative clinical endpoint studies.
FDA product-specific guidances may identify the expected evidence for a particular clobetasol dosage form. A formulation that changes excipients materially may gain differentiation but lose the simplest ANDA pathway.
The Orange Book also identifies therapeutic-equivalence ratings for approved products. Ratings can differ by dosage form and reference product. Substitution assumptions should therefore be based on the exact product, strength, route, and FDA rating rather than on the active ingredient alone.[8]
Which companies are competing in clobetasol propionate?
Competition includes originator and specialty dermatology companies, generic manufacturers, contract manufacturers, and firms developing topical delivery platforms. The competitive field is fragmented by dosage form.
Brand and specialty products
Clobex products established commercial differentiation through shampoo, lotion, spray, and foam presentations. Olux positioned foam technology for scalp and body use. Temovate established the cream and ointment franchise. These products demonstrate that the same active ingredient can support multiple commercial segments when the vehicle addresses a distinct application problem.
Generic manufacturers
Generic competition is strongest in conventional creams, ointments, gels, and solutions. Generic manufacturers compete on:
- Unit price.
- Supply reliability.
- Pharmacy substitution.
- Tube and pump packaging.
- Product availability across strengths and sizes.
Less commoditized opportunities exist in foam, shampoo, metered spray, and specialized scalp packaging because manufacturing, device qualification, and bioequivalence requirements are more demanding.
What commercial opportunities exist in clobetasol excipients?
The most actionable opportunities are:
- A propylene-glycol-free cream with low-irritation excipients.
- A low-residue lotion with controlled dosing.
- A non-aerosol foam for scalp and hair-bearing areas.
- A metered spray with a directional scalp applicator.
- A nail or palmoplantar film-forming product.
- A wash-off shampoo with improved drug deposition.
- A preservative-minimized formulation for sensitive skin.
- A contract-manufactured platform that supports several clobetasol dosage forms.
- A co-packaged regimen pairing clobetasol with a moisturizer or keratolytic product, subject to regulatory and labeling constraints.
- A formulation designed around manufacturing efficiency, reduced solvent use, and improved filling-line throughput.
Revenue potential is highest where the product can command a premium over generic cream or ointment. A new vehicle must produce a measurable benefit in adherence, application time, residue, scalp access, dosing accuracy, or tolerability. Excipients alone rarely create durable commercial protection unless they support a defensible composition, performance profile, or device combination.
How strong is the patent estate for a new clobetasol formulation?
The patent estate for the active ingredient is weak because the molecule is old and generic competition is established. A new formulation can have a stronger estate if it combines:
- A narrow but reproducible excipient range.
- A defined microstructure or particle state.
- A clinically relevant delivery advantage.
- A specialized device.
- Manufacturing parameters that are difficult to replicate.
- A method-of-use claim tied to a distinct body site or dosing schedule.
Patent strength is reduced when the formulation differs only by routine substitution of pharmaceutically acceptable excipients. The strongest commercial strategy is usually a layered portfolio covering composition, process, container-closure system, device, and clinically supported use.
Key Takeaways
- Clobetasol propionate is a mature, genericized corticosteroid with limited active-ingredient exclusivity.
- Excipient selection controls drug release, penetration, residue, stability, and tolerability.
- Foam, shampoo, lotion, spray, scalp, nail, and low-irritation products offer the clearest commercial differentiation.
- Propylene glycol, surfactants, fatty alcohols, petrolatum, polymers, and propellants are central formulation decision points.
- FDA pathway selection determines whether a product can use an ANDA, 505(b)(2), or a more burdensome clinical route.
- Orange Book and Paragraph IV risks must be reviewed for each dosage form and reference product.
- Durable IP is more likely to arise from a complete formulation-device-manufacturing system than from a routine excipient substitution.
- Premium pricing requires evidence of better usability, adherence, dosing control, tolerability, or site-specific delivery.
FAQs
Can clobetasol propionate be formulated without propylene glycol?
Yes. Glycerin, selected polyethylene glycol systems, and alternative solvent-emollient combinations may replace propylene glycol. The replacement must be evaluated for drug solubility, release, irritation, stability, and bioequivalence.
Is clobetasol foam commercially stronger than clobetasol cream?
Foam has greater differentiation in scalp and hair-bearing areas and may achieve better cosmetic acceptance. Cream generally faces stronger generic price competition.
Can a clobetasol shampoo support a new patent?
Potentially. Protection may focus on drug deposition, surfactant composition, viscosity, wash-off performance, container design, or a defined method of use. Routine shampoo reformulation alone may provide weak patent scope.
Are clobetasol excipients subject to separate FDA approval?
Excipients are reviewed as part of the drug product application. Their acceptability depends on route, concentration, prior use, product quality, and safety data. Novel or unusually concentrated excipients can increase regulatory requirements.
Is a clobetasol spray easier to develop than a foam?
Usually not. A spray may avoid aerosol propellants but introduces dose uniformity, nozzle performance, plume geometry, packaging compatibility, and scalp-directed delivery issues.
References
- U.S. Food and Drug Administration. (2024). Temovate (clobetasol propionate) cream and ointment prescribing information. FDA.
- U.S. Food and Drug Administration. (2024). Olux-E (clobetasol propionate) foam prescribing information. FDA.
- U.S. Food and Drug Administration. (2024). Clobex (clobetasol propionate) shampoo prescribing information. FDA.
- DailyMed. (2024). Clobetasol propionate topical products: labeling information. National Library of Medicine.
- U.S. Food and Drug Administration. (2024). Olux (clobetasol propionate) foam prescribing information. FDA.
- U.S. Code, 21 U.S.C. ยง 355(j). (2024). Abbreviated applications for new drugs.
- U.S. Food and Drug Administration. (2024). 505(b)(2) applications. FDA.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
